Heartwire
Late-Breaking Clinical Trials I
Dimanche 14 novembre, 15 h 45 – 17 h 13
Hall B
Dimanche 14 novembre, 15 h 45 – 17 h 13
Hall B
Télécharger le PDF  |
The Resynchronization/Defibrillation for Ambulatory Heart Failure Trial (RAFT) Dimanche 14 novembre, 15 h 45 – 15 h 55 Anthony Tang, University of Ottawa Heart Institute, ON, Canada Discussion et panel 15 h 55 – 16 h 07 (Participant : Clyde Yancy) |
| Evaluation of the HeartWare HVAD Left Ventricular Assist Device System for the Treatment of Advanced Heart Failure: Results of the ADVANCE Bridge to Transplant Trial Dimanche 14 novembre, 16 h 07 – 16 h 17 Keith D Aaronson, University of Michigan, Ann Arbor Discussion et panel 16 h 17 – 16 h 29 (Participant : Magdi Yacoub) |
|
| The Effect of Eplerenone Versus Placebo on Cardiovascular Mortality or Heart Failure Hospitalization in Subjects with NYHA Class II Chronic Systolic Heart Failure (EMPHASIS-HF Dimanche 14 novembre, 16 h 29 – 16 h 39 Michel Komajda, Université Pierre et Marie Curie, Paris, France |
|
| ALPHA OMEGA: Effect of low doses of n-3 fatty acids on cardiovascular diseases in post-MI patients Dimanche 29 août, 11 h 54 – 12 h 0 Faiez Zannad, INSERM, Université de Nancy, Vandœuvre-lès-Nancy, France Discussion et panel 16 h 39 – 16 h 51 (Participante : Lynne Warner Stevenson) |
|
| Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial
(ASCEND-HF)
Dimanche 14 novembre, 16 h 51 – 17 h 01 Adrian F Hernandez, Duke Clinical Research Institute, Durham, NC, É.-U. Discussion et panel 17 h 01 – 17 h 13 (Participant : Eugene Braunwald) |
Late-Breaking Clinical Trials II
Lundi 15 novembre, 10 h 45 – 12 h 13
Hall B
Lundi 15 novembre, 10 h 45 – 12 h 13
Hall B
|
Stroke Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation (ROCKET AF) Lundi 15 novembre, 10 h 45 – 11 h 07 Manesh R Patel for ROCKET AF Executive Steering Committee, Duke University, Durham, NC, É.-U. Discussion et panel 10 h 55 – 11 h 29 (Participante : Elaine M Hylek) |
| Primary Results From the SMART AV Trial: A Randomized Trial Comparing Empiric, Echocardiographic Guided and Algorithmic AV Delay Programming in Cardiac ResynchronizationTherapy (CRT) Lundi 15 novembre, 11 h 07 – 11 h 17 Kenneth A Ellenbogen, Medical College of Virginia, Richmond, É.-U. Discussion et panel 11 h 17 – 11 h 29 (Participant : Christophe Leclercq) |
|
| Efficacy and Safety of Prescription Omega-3-Acid Ethyl Esters (P-OM3) for the Prevention of Recurrent Symptomatic Atrial Fibrillation (AF) Lundi 15 novembre, 11 h 20 – 11 h 29 Peter R Kowey, Main Line Health Heart Center Lankenau Hospital, Wynnewood, PA, É.-U. Discussion et panel 11 h 29 – 11 h 39 (Participante : Christine Albert) |
|
| CLOSURE I: A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients with a Stroke or Transient Ischemic Attack due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale Lundi 15 novembre, 11 h 51 – 12 h 01 Anthony Furlan, University Hospital Case Neurological Institute, Cleveland, OH, É.-U. Discussion et panel 12 h 01 – 12 h 13 (Participant : Pierre Amarenco) |
Late-Breaking Clinical Trials III
Mardi 16 novembre, 10 h 45 – 12 h 13
Hall B
Mardi 16 novembre, 10 h 45 – 12 h 13
Hall B
|
Standard Versus High-Dose Clopidogrel According to Platelet Function Testing After PCI: Results ofthe GRAVITAS Trial Mardi 16 novembre, 10 h 45 – 10 h 55 Matthew J Price, Scripps Clinic, La Jolla, CA, É.-U. Discussion et panel 10:55-11:07 (Participante : Jessica L Mega) |
| NV1FGF Gene Therapy on Amputation-Free Survival in Critical Limb Ischemia--Phase 3 Randomized Double-Blind Placebo-Controlled Trial Mardi 16 novembre, 11 h 07 – 11 h 17 William R Hiatt, University of Colorado, Denver, CO, É.-U. Discussion et panel 11 h 17 – 11 h 29 (Participant : Douglas Losordo) |
|
| Late Cardiac Death and Myocardial Infarction Associated with Late Stent Thrombosis in Large Vessel Stenting After First- or Second-Generation Drug-Eluting Compared to Bare-Metal Stents: The BASKET Prospective Evaluation Examination (BASKET PROVE) Mardi 16 novembre, 11 h 29 – 11 h 39 Christoph A Kaiser, hôpital universitaire de Bâle, Suisse Discussion et panel 11 h 39 – 11 h 51 (Participant : Marco Valgimigli) |
|
| Acetylcysteine for the Prevention of Contrast-Induced Nephropathy (ACT) Trial: A Pragmatic Multicenter Randomized Trial to Evaluate the Efficacy of Acetylcysteine for the Prevention of Renal Outcomes in Patients Undergoing Coronary and Vascular Angiography Mardi 16 novembre, 11 h 51 – 12 h 01 Otavio Berwanger, São Paulo Cardiac Hospital, Brésil Discussion et panel 12 h 01 – 12 h 13 (Participant : Brahmajee K Nallamothu) |
Late-Breaking Clinical Trials IV
Mercredi 17 novembre, 10 h 45 – 12 h 13
Hall B
Mercredi 17 novembre, 10 h 45 – 12 h 13
Hall B
|
The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT): Testing C-Reactive Protein at Baseline and On-Treatment as an Independent Predictor of Cardiovascular Outcomes
Mercredi 17 novembre, 10 h 45 – 10 h 55 Peter S Sever, Imperial College, Londres, R.-U. Discussion et panel 10 h 55 – 11 h 07 (Participant : Donald M Lloyd-Jones) |
| Primary Results of the DEFINE Trial: Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib Mercredi 17 novembre, 11 h 07 – 11 h 17 Christopher P Cannon, TIMI Study Group, Boston, MA, É.-U. Discussion et panel 11 h 17 – 11 h 29 (Participant : Thomas F Luscher) |
|
| Results of the First Major Clinical Trial of an Oral Agent Inducing ApoA1 Synthesis: A New Approach to HDL Raising and CV Risk Modification Mercredi 17 novembre, 11 h 29 – 11 h 39 Stephen J Nicholls, Cleveland Clinic, OH, É.-U. Discussion et panel 11 h 39 – 11 h 51 (Participant : Eliot A Brinton) |
|
| Symplicity HTN-2: International, Multicenter, Prospective, Randomized, Controlled Trial of Endovascular Selective Renal Sympathetic Denervation for the Treatment of Hypertension Mercredi 17 novembre, 11 h 51 – 12 h 01 Murray Esler, Baker IDI Heart and Diabetes Inst, Melbourne, Australie Discussion et panel 12 h 01 – 12 h 13 (Participante : Suzanne Oparil) |
